Trial reportJCO clinical cancer informatics2022
Pertuzumab Plus Trastuzumab for Treatment-Refractory
Trial report in JCO clinical cancer informatics, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 11 citations in OpenAlex.
- Is there hope for HER2-positive colorectal cancer with Trastuzumab? A review of current evidence.Annals of medicine and surgery (2012) · 2026Review
- Review
- Design, Conduct, and Analysis of Externally Controlled Trials.JAMA network open · 2025Article
- Management of metastatic colorectal cancer: consensus in the Gulf Cooperation Council countries.Therapeutic advances in medical oncology · 2025Article
- Cancer registry as external control data for regulatory submission in Japan.ESMO real world data and digital oncology · 2024Review
- Examining external control arms in oncology: A scoping review of applications to date.Cancer medicine · 2024Article
- Therapeutic strategies targeting the epidermal growth factor receptor signaling pathway in metastatic colorectal cancer.World journal of gastrointestinal oncology · 2024Review
- Phase I study of A166, an antibody‒drug conjugate in advanced HER2-expressing solid tumours.NPJ breast cancer · 2023Article
- Resistance to targeted therapy in metastatic colorectal cancer: Current status and new developments.World journal of gastroenterology · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 3 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeWe compared overall survival (OS) in patients with human epidermal growth factor receptor 2 (
methodsA noninterventional study was conducted using patient-level data from MyPathway participants receiving PER-HER and real-world patients with
resultsThe PER-HER arm comprised 57 patients enrolled in the MyPathway study by August 1, 2017 (data cutoff); the external control arm comprised 18 patients (27 index dates) with
conclusionDespite a small sample size, these findings suggest that PER-HER could have a potential OS benefit for this population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.